Effect of Xuesaitong Dropping Pill Combined with Dapagliflozin in the Treatment of Type 2 Diabetes Mellitus Combined with Chronic Heart Fail-ure and Their impact on Improvement of PTS

ZHANG Lihui; LI Ming; CHENG Lanfang

doi:10.3969/j.issn.1002-3429.2024.05.016

Abstract：Objective To explore the effect of Xuesaitong dropping pills combined with Dapagliflozin in the treatment of type 2 diabetes mellitus(T2DM)combined with chronic heart failure(CHF)and its effects on blood glucose metabolism,cardiac function and prethrombotic state(PTS).Methods A total of 90 patients with T2DM and CHF treated from July 2022 to July 2023 were selected,and divided into the research group and the control group,with 45 patients in each group.Both groups were treated with anti-heart failure therapies such as cardiotonic and diuretic therapy.On this basis,the control group was treated with Dapagliflozin and the research group was treated with Xuesaitong dropping pills combined with Dapagliflozin.At 3 months after treatment,the therapeutic effects and adverse reactions of the two groups were compared.The blood glucose index,cardiac function index,PTS index,heart failure symptoms(Lee's heart failure score),quality of life[Minnesota Liv-ing with Heart Failure Questionnaire(MLHFQ)score],serum Nexilin,soluble suppression of tumorigenesis-2(sST2)lev-els,and adverse reactions before and after treatment were compared between the two groups.Results The total effective rate of the research group was 88.89%(40/45),which was significantly higher than that of the control group(71.11%,32/45)(P＜0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Compared with those before treatment,the fasting blood glucose,glycosylated hemoglobin,and postprandial 2-hour blood glucose levels in peripheral blood of both groups decreased at 1 month and 3 months after treatment(P＜0.05).Com-pared with the control group,the left ventricular ejection fraction increased at 1 month and 3 months after treatment in the re-search group,while the left ventricular end-diastolic diameter,left ventricular end-systolic diameter,and serum amino-termi-nal pro-brain natriuretic peptide level decreased(P＜0.01).Compared with the control group,the serum tissue-type plas-minogen activator and plasminogen activator inhibitor-1 levels increased,while fibrinogen,thromboxane B2,Nexilin,and sST2 levels decreased at 1 month and 3 months after treatment in the research group(P＜0.01).Compared with the control group,the Lee's heart failure score and MLHFQ score decreased at 1 month and 3 months after treatment in the research group(P＜0.01).Conclusion On the basis of anti-heart failure therapies,Xuesaitong dropping pills combined with Dapagliflozin is effective in the treatment of T2DM with CHF,which can improve cardiac function,glycemic metabolism,and PTS status,enhance quality of life,alleviate the progression of heart failure,and has certain safety.This may be related to the regulation of Nexilin and sST2 expression.